Australia is gain access to a groundbreaking treatment for obesity: Retatrutide. This new dual agonist – acting on both GLP-1 and GIP receptors – has significant results in international studies, indicating substantial drops in BMI. While regulatory clearance is pending with Australian regulators, a number of individuals struggling being overwe… Read More